Piper Sandler Initiates Coverage on Monopar Therapeutics (NASDAQ:MNPR)

Equities researchers at Piper Sandler assumed coverage on shares of Monopar Therapeutics (NASDAQ:MNPR) in a research note issued on Friday,Benzinga reports. The brokerage set an “overweight” rating and a $72.00 price target on the stock. Piper Sandler’s price objective indicates a potential upside of 194.36% from the stock’s previous close.

A number of other analysts have also weighed in on the company. Rodman & Renshaw initiated coverage on Monopar Therapeutics in a research note on Friday, October 11th. They issued a “buy” rating and a $50.00 target price on the stock. HC Wainwright lifted their price objective on shares of Monopar Therapeutics from $6.00 to $22.00 and gave the company a “buy” rating in a report on Monday, November 11th.

Monopar Therapeutics Trading Down 2.8 %

Shares of MNPR opened at $24.46 on Friday. The company’s fifty day simple moving average is $21.62 and its 200-day simple moving average is $10.55. The company has a market cap of $129.10 million, a P/E ratio of -12.42 and a beta of 1.23. Monopar Therapeutics has a twelve month low of $1.54 and a twelve month high of $38.50.

Monopar Therapeutics (NASDAQ:MNPR) last posted its quarterly earnings data on Friday, November 8th. The company reported ($0.37) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.46) by $0.09. Analysts predict that Monopar Therapeutics will post -1.65 earnings per share for the current fiscal year.

Insider Activity

In other Monopar Therapeutics news, CFO Karthik Radhakrishnan acquired 1,550 shares of the business’s stock in a transaction that occurred on Monday, October 28th. The shares were bought at an average cost of $16.25 per share, with a total value of $25,187.50. Following the completion of the acquisition, the chief financial officer now directly owns 1,550 shares in the company, valued at $25,187.50. This represents a ∞ increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders own 34.90% of the company’s stock.

About Monopar Therapeutics

Monopar Therapeutics Inc, a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. Its lead product candidate in development is Validive, a clonidine hydrochloride mucobuccal tablet that is in Phase 2b/3 clinical trial for the prevention of chemoradiotherapy induced severe oral mucositis in patients with oropharyngeal cancer.